Shield Therapeutics is focused on the development and commercialisation of novel therapies to treat rare diseases or those with significant unmet medical need.

The company was founded in 2008 and is currently preparing to undertake a global pivotal Phase III programme for its lead asset, ST10-021, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease.